Table 1.
Subtype A (82 subjects, 1,833 samples) | Subtype D (32 subjects, 781 samples) | |
---|---|---|
Age at infection, mean (SD) | 26.5 (4.7) | 27.3 (5.6) |
Duration of infection | ||
0–3 months | 73.2% (41/56) | 26.8% (15/56) |
4–6 months | 69.7% (101/145) | 30.3% (44/145) |
7–12 months | 71.2% (153/215) | 28.8% (62/215) |
13–24 months | 73.4% (282/384) | 26.6% (102/384) |
25–48 months | 70.2% (552/786) | 29.8% (234/786) |
49+ months | 68.5% (704/1,028) | 31.5% (324/1,028) |
Sample year | ||
2001–2002 | 62.2% (143/230) | 37.8% (87/230) |
2003–2004 | 67.9% (360/530) | 32.1% (170/530) |
2005–2006 | 72.1% (498/691) | 27.9% (193/691) |
2007–2008 | 72.4% (566/782) | 27.6% (216/782) |
>2008 | 69.8% (266/381) | 30.2% (115/381) |
CD4 cell count (cells/μl) | ||
>500 | 73.0% (832/1,140) | 27.0% (308/1,140) |
499–200 | 70.1% (808/1,153) | 29.9% (345/1,153) |
199–50 | 61.4% (94/153) | 38.6% (59/153) |
<50 | 36.4% (4/11) | 63.6% (7/11) |
No data | 60.5% (95/157) | 39.5% (62/157) |
Viral load (copies/ml) | ||
>50,000 | 61.5% (235/382) | 38.5% (147/382) |
49,999–10,000 | 76.5% (248/324) | 23.5% (76/324) |
9,999–400 | 77.0% (245/318) | 23.0% (73/318) |
<400 | 47.7% (142/298) | 52.3% (156/298) |
No data | 74.5% (963/1,292) | 25.5% (329/1,292) |
Time on ART | ||
Not on ART | 74.9% (1691/2,256) | 25.1% (565/2,256) |
ART <1 year | 56.5% (87/154) | 43.5% (67/154) |
ART >1 year | 27.0% (55/204) | 73.0% (149/204) |
ART, antiretroviral treatment; SD, standard deviation.